Bulletin Board Volume 13, Number 3 (July, 1998) |
Four new members have been approved by Health and Human Services Secretary Dr. Donna E. Shalala to join NIDA's National Advisory Council on Drug Abuse, which provides direction and oversight for the Institute's scientific programs and policies. The Council meets three times a year and provides the second level of review for NIDA grant applications. Members include experts in health and scientific disciplines related to drug abuse, public policy, health policy, law, economics, and management.
The four new members began their terms at the Council meeting in May. The new members are:
Dr. Frank Vocci |
Dr. Frank J. Vocci, Jr., has been named director of NIDA's Medications Development Division (MDD). Since April 1996, Dr. Vocci has served as the Division's acting director. As Division director, Dr. Vocci oversees MDD's research to identify, evaluate, and develop new medications to treat drug dependence and addiction and other brain and behavioral disorders. The Division also ensures that medications are developed to meet the Food and Drug Administration's (FDA) requirements for approving new drugs. To ensure that the research and review of promising new treatment medications are conducted expeditiously, the Division works closely with FDA, academic centers, and pharmaceutical and chemical companies. A pharmacologist with 20 years of experience studying the pharmacology and toxicity of new drugs, Dr. Vocci first joined NIDA in 1989 as chief of MDD's Developmental Therapeutics Branch. Before coming to NIDA, he reviewed new drug applications for FDA. He has served as a guest researcher in the Clinical Neurosciences Branch of the National Institute of Mental Health. |
The National Institutes of Health (NIH) has created 21 new study sections that are responsible for reviewing a wide range of basic and clinical neuroscience grant applications. The study sections are part of NIH's new Center for Scientific Review (CSR), formerly the Division of Research Grants. Most new investigator-initiated neuroscience grant applications seeking NIDA support will now be reviewed initially by the new study sections, which have been organized into three Initial Review Groups:
For information about each study section's review responsibilities, visit the CSR World Wide Web site at http://www.csr.nih.gov/. Click on Referral & Review, then click on Initial Review Groups. Questions about the study sections should be directed to Dr. Carole Jelsema for the MDCN Review Group, (301) 435-1248; Dr. Larry Stanford for the IFCN Review Group, (301) 435-1255; and Dr. Joe Marwah for the BDCN Review Group, (301) 435-1253.
NIDA NOTES - Volume 13 Number 3 |
NIDA Home | Site Map | Search | FAQs | Accessibility | Privacy | FOIA (NIH) | Employment | Print Version
|